万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生2>>药学
您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生1>>肿瘤学

JOURNAL OF ONCOLOGY PHARMACY PRACTICE《肿瘤药学实践杂志》 (官网投稿)

简介
  • 期刊简称J ONCOL PHARM PRACT
  • 参考译名《肿瘤药学实践杂志》
  • 核心类别 SCIE(2024版), 目次收录(维普), 目次收录(知网),外文期刊,
  • IF影响因子
  • 自引率15.40%
  • 主要研究方向医学-ONCOLOGY肿瘤学;PHARMACOLOGY & PHARMACY药学

主要研究方向:

等待设置主要研究方向
医学-ONCOLOGY肿瘤学;PHARMACOLOGY & PHARMACY药学

JOURNAL OF ONCOLOGY PHARMACY PRACTICE《肿瘤药学实践杂志》(一年8期). Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated ...[显示全部]
征稿信息

万维提示:

1、投稿方式:官网投稿。

2、期刊网址:https://journals.sagepub.com/home/opp

3、投稿网址:

https://mc.manuscriptcentral.com/jopp

4、期刊刊期:一年出版8期。

          20220104日星期二

                   

投稿须知【官网信息】

 

JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Manuscript Submission Guidelines:

Manuscript Submission Guidelines: Journal of Oncology Pharmacy Practice

This Journal is a member of the Committee on Publication Ethics.

This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

Please read the guidelines below then visit the Journals submission site http://mc.manuscriptcentral.com/jopp to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.

Only manuscripts of sufficient quality that meet the aims and scope of Journal of Oncology Pharmacy Practice will be reviewed.

There are no fees payable to submit or publish in this journal.

As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.

1.1 Aims & Scope

Before submitting your manuscript to Journal of Oncology Pharmacy Practice, please ensure you have read the Aims & Scope.

The Journal of Oncology Pharmacy Practice (JOPP) is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer and is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP).

JOPP publishes cancer drug therapy and cancer disease management review articles, research papers, pertinent case reports, editorials, and consensus guidelines that drive clinical practice.

As the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP), JOPP contains articles about practical issues relating to oncology pharmacy including papers about safe handling of cytotoxic agents.

1.2 Article Types

Manuscripts are considered for publication with the understanding that they have not been published previously and are not under consideration by another publication. However, the journal will consider manuscripts previously presented as limited posters and abstracts during conferences or in supplements.

The journal publishes review articles, original research papers, practice guidelines, practice issues, case reports, letters to the editor, and editorials/commentaries.

Submissions of any article type do not have a strict restriction on word count, tables/figures or references. Submitting authors are encouraged to use what is necessary and appropriate for their manuscript, but note that the peer review process may suggest or request a reduction in any of these aspects.

Review Articles. Comprehensive and critical reviews of drug use in cancer patient care. For medication review articles please include introduction, pharmacology, pharmacokinetics/ pharmacodynamics, therapeutic use, clinical use controversies, product description (cost, special preparation and/or administrative considerations), and perspectives on use (summary paragraph including how this drug fits into current practice). For disease and supportive care management reviews include introduction, epidemiology, etiology, pathophysiology, patient presentation, common staging systems used (for malignancy treatment reviews), treatment (include surgery, radiation, but focus on drug therapy aspects), and summary. It is highly desirable to include a flow-diagram treatment algorithm to summarize disease management.

Original Research Articles. Articles should include a clear statement of purpose; a brief historical review; and a description of the methods, procedures, subjects used, statistical analysis, results, discussion, and conclusions (with clinical implications). For research involving human subjects, a statement must be included to assure that the principles set forth in the the Declaration of Helsinki 1975, revised Hong Kong 1989, were followed or that approval from a local or regional committee on human investigation was obtained. A statement must also be included attesting that informed consent was obtained from each subject or the subject's guardian.

Practice Guidelines. Institutional policies on medication use with outcome indicators.

Practice Issues. Reports of innovative services, policies, or outcome measure tools.

Case Series/Reports. Include an introduction justifying the case report, the case description, and discussion.

Letters to the Editor. Brief comments on articles published in the Journal or other information of interest to our readers.

Editorials/ Commentaries. Expression of opinions about controversial therapeutic areas or comments about practice-related issues are encouraged.

1.2.1 Abstract guidelines

Please ensure you include the following criteria in your abstract:

Research Article. Introduction (description of rationale for study), Methods (brief description of methods or study design), Results (summary of significant results), and Conclusions (succinct statement of data interpretation).

1.2 Article Types

Manuscripts are considered for publication with the understanding that they have not been published previously and are not under consideration by another publication. However, the journal will consider manuscripts previously presented as limited posters and abstracts during conferences or in supplements.

The journal publishes review articles, original research papers, practice guidelines, practice issues, case reports, letters to the editor, and editorials/commentaries.

Submissions of any article type do not have a strict restriction on word count, tables/figures or references. Submitting authors are encouraged to use what is necessary and appropriate for their manuscript, but note that the peer review process may suggest or request a reduction in any of these aspects.

Review Articles. Comprehensive and critical reviews of drug use in cancer patient care. For medication review articles please include introduction, pharmacology, pharmacokinetics/ pharmacodynamics, therapeutic use, clinical use controversies, product description (cost, special preparation and/or administrative considerations), and perspectives on use (summary paragraph including how this drug fits into current practice). For disease and supportive care management reviews include introduction, epidemiology, etiology, pathophysiology, patient presentation, common staging systems used (for malignancy treatment reviews), treatment (include surgery, radiation, but focus on drug therapy aspects), and summary. It is highly desirable to include a flow-diagram treatment algorithm to summarize disease management.

Original Research Articles. Articles should include a clear statement of purpose; a brief historical review; and a description of the methods, procedures, subjects used, statistical analysis, results, discussion, and conclusions (with clinical implications). For research involving human subjects, a statement must be included to assure that the principles set forth in the the Declaration of Helsinki 1975, revised Hong Kong 1989, were followed or that approval from a local or regional committee on human investigation was obtained. A statement must also be included attesting that informed consent was obtained from each subject or the subject's guardian.

……                                  

更多详情:

https://journals.sagepub.com/author-instructions/OPP


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭